XORTX Therapeutics Inc. (NASDAQ: XRTX) announced the completion of its acquisition of VB4-P5, a kidney anti-fibrotic asset from Vectus Biosystems ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE